ACT-AD’s Ninth Annual FDA/AD Allies Meeting Is November 16

The Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition will host its ninth annual meeting on November 16, 2016, from 9:30 a.m. to 4 p.m at the Bethesda North Marriott Hotel and Conference Center (5701 Marinelli Road, North Bethesda, Maryland, 20852).  The theme of this year’s meeting is: Starting with the End in Mind: Aligning the Science to Close Gaps in Alzheimer’s Disease Therapeutic Development. 

Here’s a description:

In September of 2015, the Accelerate Cure/Alzheimer’s Disease (ACT-AD) Coalition held its’ 8th annual meeting in response to the U.S. Food and Drug Administration’s (FDA) report on progress toward targeted drug therapy for Alzheimer’s disease (AD). This meeting began a discussion about the state of research into the underlying causes of Alzheimer’s disease and pathways for successful treatment. Participants left encouraged by significant research investments in the public and private sectors they anticipated were on track to fill the knowledge gaps FDA identified.

ACT-AD’s November 16, 2016 meeting will build on the 2015 gathering and explore whether federal research and regulatory review align to definitively close knowledge gaps in clinical development. The meeting will review the most recent research on Alzheimer’s disease pathology and genetics; efforts to identify reliable biomarkers in disease-modifying treatment trials; and novel symptomatic approaches to improve major behavioral and psychiatric aspects of the disease. The program will conclude with an open exchange about how findings from current studies can be practically applied to improve the prospects for successful Alzheimer’s disease treatment in the future.